Entero Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Entero Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2015 to 2023.
  • Entero Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$2.58M, a 24.8% increase year-over-year.
  • Entero Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$9.92M, a 36.7% increase year-over-year.
  • Entero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$15.8M, a 7.97% decline from 2022.
  • Entero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$14.6M, a 75% increase from 2021.
  • Entero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$58.5M, a 79.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$15.8M -$1.17M -7.97% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-29
2022 -$14.6M +$43.9M +75% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 -$58.5M -$25.9M -79.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-20
2020 -$32.7M -$17.5M -115% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 -$15.2M -$1.64M -12.1% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-31
2018 -$13.5M -$2.44M -22% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-30
2017 -$11.1M +$3.5M +24% Jan 1, 2017 Dec 31, 2017 10-K 2019-04-01
2016 -$14.6M -$8.66M -146% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-16
2015 -$5.93M Jan 1, 2015 Dec 31, 2015 10-K 2017-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.